Published: 2020-08-25

Neurofibromatosis type-1 with seizures and cerebrovascular malformation: a case study

Nishant Gopaal, Jagdish N. Sharma, Priyanshu Mathur, Vijay Agarwal, Laxman Jadoun


Neurofibromatosis type 1 (NF1) is the most common autosomal dominant neurocutaneous among humans. Epilepsy is more prevalent in NF1 patients than in the general population. NF1 vasculopathy is also a significant but underrecognized complication of the disease, affecting both arterial and venous blood vessels. Herein, we report a 2 year old female child with seizures and multiple cafe-au-lait spots on the body. The patient was diagnosed with NF1 based on clinical findings and family history. MRI Brain revealed middle cerebral artery dysplasia. Here we discuss diagnostic and treatment challenges and briefly reviews the existing literature.


Case report, Neurocutaneous syndromes, Neurofibromatosis type 1, Epilepsy, seizures, Vascular dysplasia, Vasculopathy, Café-au-lait spots

Full Text:



Evans DG, Howard E, Giblin C, Spencer H, Huson SM, Lalloo F. Birth incidence and prevalence of tumor prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327.

Stephens K, Kayes L, Riccardi VM, Rising M, Sybert VP, Pagon RA. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet. 1992;88:279.

Friedman JM, Arbiser J, Epstein JA. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med. 2002;4:105-11.

Hsieh HY, Fung HC, Wang CJ, Chin SC, Wu T. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure. 2011;20: 606-11.

NIH consensus development program. Neurofibromatosis, national institutes of health consensus development conference statement. Available at: Neurofibramatosis064html.htm. Accessed on 20 June 2020.

DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000; 105:608.

Vivarelli R, Grosso S, Calabrese F, Farnetani M, Di Bartolo R, Morgese G, et al. Epilepsy in neurofibromatosis. Journal of Child Neurology. 2003;18:338-42.

Serdaroglu E, Konuskan B, Karli Oguz K, Gurler G, Yalnizoglu D, Anlar B. Epilepsy in neurofibromatosis type1: Diffuse cerebral dysfunction?. Epilepsy Behav. 2019;98:6.

Ostendorf AP, Gutmann DH, Weisenberg JLZ. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia. 2013;54(10):1810-4.

Santoro C, Bernardo P, Coppola A, Pugliese U, Cirillo M, Giugliano T, et al. Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?. Italian Journal of Pediatrics. 2018; 44:41.

Kulkantrakorn K, Geller TJ. Seizures in neurofibromatosis. Pediatr Neurol. 1998;19:347-50.

Lin AE, Birch P, Korf BR, Tenconi R, Niimura M, Poyhonen M, et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis type I. Am J Med Genet. 2000;95:108-17.

Oderich G., Sullivan TM, Gloviczki P, Miller DV, Babovic-Vuksanovic D, Macedo TA, et al. Vascular abnormalities in patientswith neurofibromatosis syndrome type I: Clinical spectrum, management, and results. J Vascular Surg. 2007;46(3):475-84.

Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology. 2005;64:553.

Rea D, Brandsema JF, Armstrong D, Parkin PC, DeVeber G, MacGregor D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics. 2009;124:e476.